ASH Summit on Immunotherapies for Hematologic Diseases

Why is the success of immunotherapies and other targeted therapies such as gene therapy so variable within different patient populations? How can we improve these targeted therapies for widespread use in patients with hematologic diseases? Help answer these questions and more at the ASH Summit on Immunotherapies for Hematologic Diseases.

For more details – ASH Summit